CN106389451B - A kind of pharmaceutical composition and its preparation method and application for treating inflammatory bowel disease - Google Patents
A kind of pharmaceutical composition and its preparation method and application for treating inflammatory bowel disease Download PDFInfo
- Publication number
- CN106389451B CN106389451B CN201611055105.2A CN201611055105A CN106389451B CN 106389451 B CN106389451 B CN 106389451B CN 201611055105 A CN201611055105 A CN 201611055105A CN 106389451 B CN106389451 B CN 106389451B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- treatment
- parts
- ginsenoside
- ulcerative colitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of pharmaceutical compositions for treating inflammatory bowel disease, including the following component prepared according to parts by weight: 20~40 parts of ginsenoside, 20~40 parts of enoxolone, 20~40 parts and 5~15 parts of jamaicin of zingiberene.The pharmaceutical composition for the treatment of inflammatory bowel disease provided herein, including ginsenoside, enoxolone, zingiberene and jamaicin, have many advantages, such as that significant effect, toxic side effect are small, furthermore ginsenoside and zingiberene combine the effect for being improved immunity of organisms, reduce the side effect of anti-inflammation drugs.The preparation method of the pharmaceutical composition for the treatment of inflammatory bowel disease provided herein, component are easy to get, and it is convenient, simple, easily operated to have many advantages, such as, suitable for mass production and extensive use.The pharmaceutical composition for the treatment of enteritis provided by application is used to prepare the vein or oral administration preparation for the treatment of people or animal inflammatory bowel disease, dosage 0.02-200mg/kg.
Description
Technical field
The present invention relates to pharmaceutical technology fields, in particular to a kind of for treating the pharmaceutical composition of inflammatory bowel disease
And its preparation method and application.
Background technique
Inflammatory bowel disease (inflammatory bowel disease, IBD) is a kind of still not fully aware of chronic of cause of disease
Non-specific inflammatory bowel disease, including ulcerative colitis (UC) and Crohn disease (CD).The disease is the common disease of western countries
Disease rises year by year in Chinese disease incidence in recent years, it has also become the main reason for Chinese digestive system common disease and chronic diarrhea.
The symptom of inflammatory bowel disease (IBD) normally behaves as diarrhea, abdominal pain, tenesmus, and several cases can have appetite stimulator, Abdeminal pain
The disease of discomfort, nausea and vomiting etc..IBD onset minority is hurried, most slow, and the course of disease can divide duration, or in stage of attack and delay
The chronic process that the solution phase alternates.The inducement of breaking-out is mostly direct stimulation, fatigue, feeding desorder.Its treatment mostly uses internal medicine to control
It treats, by directly blocking certain links of inflammation occurrence and development or by inhibiting immune response anti-to reduce immune-mediated inflammation
It answers.Purpose is that induction inflammation is alleviated and it is made to maintain relieved state.Therapeutic agent mainly include salicylic acid, adrenal cortex swash
Element, immunosuppressive drug three categories, side effect is more, and the curative effect of most drugs is unstable, it is difficult to reach the mesh effectively treated
's.
In consideration of it, the present invention is specifically proposed.
Summary of the invention
The first object of the present invention is to provide a kind of pharmaceutical composition for treating inflammatory bowel disease, to solve existing Western medicine pair
Act on more, problem that curative effect is unstable, the pharmaceutical composition for treating inflammatory bowel disease, containing ginsenoside, enoxolone,
Zingiberene and jamaicin have many advantages, such as that significant effect, toxic side effect are small.
The second object of the present invention is to provide the preparation method that the pharmaceutical composition of inflammatory bowel disease is treated described in one kind,
Composition is added to medical auxiliary materials after mixing and carries out preparation, obtains the pharmaceutical composition of the treatment inflammatory bowel disease, this method
It is convenient, simple, easily operated to have many advantages, such as, suitable for mass production and extensive use.
The third object of the present invention is to provide the application that the pharmaceutical composition of inflammatory bowel disease is treated described in one kind, this is controlled
The pharmaceutical composition for treating inflammatory bowel disease is used to prepare the vein or mouth for the treatment of people or animal ulcerative colitis or Crohn disease
Take drug-delivery preparation, dosage 0.02-200mg/kg.
In order to realize above-mentioned purpose of the invention, the following technical scheme is adopted:
A kind of pharmaceutical composition for treating inflammatory bowel disease, including the following component prepared according to parts by weight:
20~40 parts of ginsenoside, 20~40 parts of enoxolone, 20~40 parts and 5~15 parts of jamaicin of zingiberene.
Ginsenoside is a kind of steroid compound --- triterpenoid saponin.It is primarily present in Panax medicinal material.Ginseng soap
The physiological activity of glycosides determines its edible and medical value.There is ginsenoside antifatigue, raising to remember, delay senescence, mention
A variety of effects such as high body's immunity, antitumor.Especially its function of improving immunity of organism, can be improved organism itself
Immunity, fight chronic inflammation.
Enoxolone has anti-inflammatory effect.Enoxolone swollen, subcutaneous meat to the granuloma induced by implantation of cotton pellets and formaldehyde foot of big white mouse
Swell property inflammation etc. of bud has an inhibiting effect, antiphlogistic effects be about cortisone or hydrogenation can pine 1/10.Its anti-inflammatory, antiallergy
Reaction and inhibition capillary permeability, antihistamine or reduction cell are related to the reactivity of stimulation.Also, enoxolone is to more
Kind acute inflammation has inhibiting effect, and anti-inflammatory effect is independent of Pituitary Adrenalcortical system.
Zingiberene also known as α-ginger are dilute, are one of Ginger P.Es, have the function of detoxicating, killing bacteria, into after organism,
A kind of oxidation resistant enzyme can be generated, there is the very strong ability to antioxidant radical.
Jamaicin is also known as berberine, is a kind of common morphinane alkaloid, molecular formula C20H18NO4.Jamaicin is to haemolysis
Property streptococcus, staphylococcus aureus, gonococcus and Freund, Shigella shigae etc. have antibacterial action, and have enhancing white
Blood cell phagocytosis also has different degrees of inhibiting effect to tubercle bacillus, plague bacillus, also has inhibition to the amoeba bacterium of rat
Effectiveness.Jamaicin has anti-curare to act on, and has peripheral decompression and refrigeration function.
Biology can be improved in the pharmaceutical composition for the treatment of inflammatory bowel disease provided herein, ginsenoside and the dilute cooperation of ginger
The immunity of body itself, and jamaicin and enoxolone have an antibacterial action, four kinds of drugs combine can confrontation from inside to outside
Inflammatory bowel disease.
Preferably, the pharmaceutical composition of the treatment inflammatory bowel disease, including the following component prepared according to parts by weight:
25~35 parts of ginsenoside, 25~35 parts of enoxolone, 25~35 parts and 8~12 parts of jamaicin of zingiberene.
The component of the pharmaceutical composition of above-mentioned treatment inflammatory bowel disease can be carried out preferred.
Preferably, the pharmaceutical composition of the treatment inflammatory bowel disease, including the following component prepared according to parts by weight:
27~33 parts of ginsenoside, 27~33 parts of enoxolone, 27~33 parts and 9~11 parts of jamaicin of zingiberene.
The component of the pharmaceutical composition of above-mentioned treatment inflammatory bowel disease can be carried out further preferred.
Preferably, the ginsenoside includes from one of the root of ginseng and American Ginseng, stem, leaf, flower, fruit or a variety of
Isolated ginsenoside monomer compound is extracted in mixing.
Other than araliaceae ginseng plant can extract saponin(e, it can also join from hot-working and separate identification in Radix Notoginseng
Out.However ginsenoside used by the application preferably is selected from araliaceae ginseng plant --- in ginseng and American Ginseng, concentration
Height, purity is good, curative effect is good.
Preferably, the ginsenoside includes Ginsenoside Rc, ginsenoside Rg1, ginsenoside Re and ginsenoside
One of Rg3, preferred ginsenoside are ginsenoside Rg1.
Ginsenoside Rg1 can enhance protein in spleen by the synthesis of promotion Human Serum Albumin, gamma globulin
Combined coefficient improves the efficiency of antigenic stimulus antibody tormation, it can also pass through improves body cAMP (cyclisation adenine-phosphoric acid core
Thuja acid) concentration stimulate the function of T, bone-marrow-derived lymphocyte mature.Panaxatriol saponins can be situated between by directly increasing leucocyte
The stability of element -6-mRNA and promote its translational efficiency, and then increase interleukin-6 to T, bone-marrow-derived lymphocyte and macrophage
Break up effect with rush.Ginsenoside Rc can promote T cell to be proliferated, and the activity of natural killer cell (NK) be improved, to improve
Immunity of organisms.
Ginsenoside Rg1 and Rg3 can inhibit Ca2+Channel reduces Ca intracellular2+Concentration, to reach the work of protection cardiac muscle
With.Ginsenoside Re then can activate cGMP dependent kinases, myosin light chain is made to remove phosphoric acid by the production quantity of increase NO
Change and generate the effect of smooth muscle relaxation, expansion blood vessel improves cardiac muscle.Ginsenoside can improve the same of autoimmunity
When, there is significant protective effect to other organs such as nerve, brains under ischemic state, effectively avoids inflammation and anti-inflammatory medicaments
Damage to body.
Preferably, described pharmaceutical composition further includes medical auxiliary materials；
It is furthermore preferred that the dosage form of described pharmaceutical composition is oral administration preparation or non-intestinal drug delivery agent；Preferably, institute
Stating oral administration preparation includes tablet, capsule, granule, pill and oral solution, and the non-intestinal drug delivery agent includes injection
Agent and powder-injection.
The preparation method of the pharmaceutical composition for the treatment of inflammatory bowel disease as described above, comprising the following steps:
Ginsenoside, enoxolone, zingiberene and jamaicin are uniformly mixed, and medical auxiliary materials are added and carry out preparation, obtain medical treatment
The pharmaceutical composition of inflammatory bowel disease.
The drug can be prepared as different dosage forms.
Preferably, the method that the mixing uses ultrasonic vibration.
Ultrasonic vibration can be such that drug is quickly uniformly mixed.
The pharmaceutical composition for the treatment of inflammatory bowel disease as described above in preparation treatment people or animal ulcerative colitis or
Application in the drug of Crohn disease medication.
The application of the pharmaceutical composition for the treatment of inflammatory bowel disease as described above, which is characterized in that the ginsenoside contains
Amount is 0.02-200mg/kg.
Compared with prior art, the invention has the benefit that
1), the pharmaceutical composition for the treatment of inflammatory bowel disease provided herein, including ginsenoside, enoxolone, zingiberene
And jamaicin, have many advantages, such as that significant effect, toxic side effect are small, furthermore ginsenoside and zingiberene, which combine, is improved immunity of organisms
Effect, reduce the side effect of anti-inflammation drugs.
2), the preparation method of the pharmaceutical composition for the treatment of inflammatory bowel disease provided herein, component are easy to get, and have side
Just, simply, it is easily operated the advantages that, it is suitable for mass production and be widely applied.
3), the pharmaceutical composition for the treatment of inflammatory bowel disease provided by application is used to prepare treatment people or the exedens knot of animal
The vein or oral administration preparation of enteritis or Crohn disease, the content of ginsenoside are 0.02-200mg/kg.
Specific embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the invention.It is not specified in embodiment specific
Condition person carries out according to conventional conditions or manufacturer's recommended conditions.Reagents or instruments used without specified manufacturer is
The conventional products that can be obtained by commercially available purchase.
Embodiment 1
The pharmaceutical composition for the treatment of inflammatory bowel disease includes following components provided by the present embodiment:
Ginsenoside 20mg, enoxolone 20mg, zingiberene 20mg, jamaicin 5mg.
The preparation method of the pharmaceutical composition of the treatment inflammatory bowel disease, comprising the following steps:
After said medicine component is mixed after mixing by ultrasonic vibration, capsule is prepared into after medical auxiliary materials being added.
Embodiment 2
The pharmaceutical composition for the treatment of inflammatory bowel disease includes following components provided by the present embodiment:
Ginsenoside 40mg, enoxolone 40mg, zingiberene 40mg, jamaicin 15mg.
The preparation method of the pharmaceutical composition of the treatment inflammatory bowel disease, comprising the following steps:
After said medicine component is mixed after mixing by ultrasonic vibration, tablet is prepared into after medical auxiliary materials being added.
Embodiment 3
The pharmaceutical composition for the treatment of inflammatory bowel disease includes following components provided by the present embodiment:
Ginsenoside 35mg, enoxolone 35mg, zingiberene 35mg and jamaicin 12mg.
The preparation method of the pharmaceutical composition of the treatment inflammatory bowel disease, comprising the following steps:
After said medicine component is mixed after mixing by ultrasonic vibration, injection is prepared into after medical auxiliary materials being added
Agent.
Embodiment 4
The pharmaceutical composition for the treatment of inflammatory bowel disease includes following components provided by the present embodiment:
Ginsenoside 25mg, enoxolone 25mg, zingiberene 25mg and jamaicin 8mg.
The preparation method of the pharmaceutical composition of the treatment inflammatory bowel disease, comprising the following steps:
After said medicine component is mixed after mixing by ultrasonic vibration, particle is prepared into after medical auxiliary materials being added
Agent.
Embodiment 5
The pharmaceutical composition for the treatment of inflammatory bowel disease includes following components provided by the present embodiment:
Ginsenoside 80mg, enoxolone 80mg, zingiberene 80mg and jamaicin 20mg.
The preparation method of the pharmaceutical composition of the treatment inflammatory bowel disease, comprising the following steps:
After said medicine component is mixed after mixing by ultrasonic vibration, it is prepared into after addition medical auxiliary materials oral
Liquid.
The experiment of one drug effect animality of experimental example
1. material
1.1 animal material
Animal is Wistar big white mouse, 180~200g of weight, purchased from purchased from Jining Shandong biology Co., Ltd, licensing
Number: SCXK (Shandong) 20150015.
1.2 drug
The pharmaceutical composition of inflammatory bowel disease is treated provided by the embodiment 1,2,5.
Comparative example 1 is that salicylazosulfapyridine (SASP) (salicylazosulfapyridine is the salicylic acid system treated earliest for IBD
Agent).
2 methods
80 rats are randomly divided into blank group, model group, small dose group, middle dose group, large dosage of group, SASP by weight
Group, every group 8, half male and half female.2.4.6- trinitrobenzene sulfonic acid (the trinitro- for being reported and being improved using Morris
Benzene-sulfonic acid, TNBS)/ethanol solution enema preparation UC rat model.Low, middle and high dose groups are adopted respectively
The pharmaceutical composition of the inflammatory bowel disease provided by the embodiment of the present application 1,2 and 5, respectively according to ginsenoside 20,40,80mg/
Kg, 1ml/100g, beginning stomach-filling in the 3rd day after modeling, blank group and model group give same amount of normal saline, are administered 14 days altogether.Often
Its record rat weight, and rat ordinary circumstance is observed, including hair, the state of mind, excrement situation.
Rat successive administration 14d, is deprived of food but not water for 24 hours, 10% chloraldurate (3ml/kg) intraperitoneal injection of anesthesia, to rat
Operating table is fixed on after general anesthesia immediately, is cut along abdomen median line, blunt separation tissue, abundant exposed Rats abdomen cardinal vein, one
Secondary property syringe extracts blood sample 5ml, is centrifuged (2000r/min, 10min) after standing 30min, and serum packing is extracted after centrifugation, and
- 80 DEG C of refrigerators are placed in save backup.After taking blood, observation colon general form change and with the situations such as abdominal cavity adhesion, using passivity
Separation method separation rat colon tissue (from anus to caecum about 8cm or more), is splitted, brine ice rinses dry along the mesenterium longitudinal axis
Only, and by colonic tissue it is sufficiently spread out, tiles, fixes, a situation arises for observation inflammation and ulcer, carries out colonic tissue general form
It scores (colon macroscopic damage index, CMDI), pathological tissues is taken to measure IFN-γ, IL-2, TNF-α, IL-
4。
Experimental data is handled using SPSS17.0 statistical software, data are indicated with mean ± standard deviation, metering money
Material uses one-way analysis of variance, and P < 0.05 is that difference is statistically significant.As a result see Table 1 for details:
1 rat DAI, CMDI statistical form (x ± s, n=10) of table
| Group | DAI | CMDI |
| Normal group | 0.00±0.00 | 0.00±0.00 |
| Model group | 3.83±0.34▲ | 3.53±0.41▲ |
| Small dose group | 2.98±0.21 | 2.9±0.67 |
| Middle dose group | 2.02±0.22■ | 1.61±0.31■ |
| Large dosage of group | 2.29±0.35□ | 1.55±0.51■ |
| Comparative example 1 | 2.37±0.29□ | 1.66±0.44■ |
Note: compared with normal group,▲P < 0.01,△P<0.05；Compared with model group,□P < 0.05,■ P<0.01。
Using enzyme-linked immunization, different groups of rat blood serum cell factors such as IFN-γ, IL-2, TNF-α, IL-4 water are detected
It is flat.As a result: compared with normal group, IFN-γ, IL-2, TNF-α are significantly raised, and cell factor IL-4 is substantially reduced, and have system
Meter learns difference (P < 0.05)；Compared with model group, IFN-γ, IL-2, TNF-α are substantially reduced, and cell factor IL-4 obviously rises
High (P < 0.05), middle dosage, dosage group group IFN-γ/IL-4 ratio are substantially reduced, and have statistical difference.As a result it is detailed in table
2。
2 each group rat blood serum IL-2 of table, TNF-α, IFN-γ, IL-4 comparision contents (x ± s, n=10)
Note: compared to the blank group,▲P < 0.01,△P<0.05；Compared with model group,□P < 0.05,■ P<0.01。
The experimental results showed that the pharmaceutical composition for the treatment of inflammatory bowel disease provided herein has apparent treatment ulcer
The effect of property colitis.Wherein, ginsenoside Rg1: enoxolone: α-zingiberene: the proportion compatibility of jamaicin mixture is 3:3:
3:1 effect is best.
In conclusion the pharmaceutical composition for the treatment of inflammatory bowel disease provided herein, including ginsenoside, Radix Glycyrrhizae time
Acid, zingiberene and jamaicin, have many advantages, such as that significant effect, toxic side effect are small, and furthermore ginsenoside and zingiberene, which combine, is improved machine
The effect of body immunity reduces the side effect of anti-inflammation drugs.The pharmaceutical composition for the treatment of inflammatory bowel disease provided herein
Preparation method, component are easy to get, and it is convenient, simple, easily operated to have many advantages, such as, suitable for mass production and extensive use.Application institute
The pharmaceutical composition of the treatment inflammatory bowel disease of offer is used to prepare treatment people or animal ulcerative colitis or Crohn disease
Vein or oral administration preparation, dosage 0.02-200mg/kg.
Although illustrate and describing the present invention with specific embodiment, it will be appreciated that without departing substantially from of the invention
Many other change and modification can be made in the case where spirit and scope.It is, therefore, intended that in the following claims
Including belonging to all such changes and modifications in the scope of the invention.
Claims (11)
1. a kind of pharmaceutical composition for treating ulcerative colitis, which is characterized in that as follows including what is prepared according to parts by weight
Component:
20 ~ 40 parts of ginsenoside, 20 ~ 40 parts of enoxolone, 20 ~ 40 parts and 5 ~ 15 parts of jamaicin of zingiberene；
The ginsenoside is ginsenoside Rg1.
2. the pharmaceutical composition for the treatment of ulcerative colitis according to claim 1, which is characterized in that including according to weight
The following component that number is prepared:
25 ~ 35 parts of ginsenoside, 25 ~ 35 parts of enoxolone, 25 ~ 35 parts and 8 ~ 12 parts of jamaicin of zingiberene.
3. the pharmaceutical composition for the treatment of ulcerative colitis according to claim 1, which is characterized in that including according to weight
The following component that number is prepared:
27 ~ 33 parts of ginsenoside, 27 ~ 33 parts of enoxolone, 27 ~ 33 parts and 9 ~ 11 parts of jamaicin of zingiberene.
4. the pharmaceutical composition for the treatment of ulcerative colitis according to claim 1-3, which is characterized in that described
Ginsenoside include extracted from one of the root of ginseng and American Ginseng, stem, leaf, flower, fruit or a variety of mixing it is isolated
Ginsenoside monomer compound.
5. the pharmaceutical composition for the treatment of ulcerative colitis according to claim 4, which is characterized in that the pharmaceutical composition
Object further includes medical auxiliary materials.
6. the pharmaceutical composition for the treatment of ulcerative colitis according to claim 5, which is characterized in that the pharmaceutical composition
The dosage form of object is oral administration preparation or non-intestinal drug delivery agent.
7. the pharmaceutical composition for the treatment of ulcerative colitis according to claim 6, which is characterized in that the oral administration
Preparation includes tablet, capsule, granule, pill and oral solution, and the non-intestinal drug delivery agent includes injection.
8. the pharmaceutical composition for the treatment of ulcerative colitis according to claim 7, which is characterized in that the injection packet
Include powder-injection.
9. the preparation method of the pharmaceutical composition for the treatment of ulcerative colitis according to claim 1-8, special
Sign is, comprising the following steps:
Ginsenoside, enoxolone, zingiberene and jamaicin are uniformly mixed, and medical auxiliary materials are added and carry out preparation, obtain medical treatment ulcer
The pharmaceutical composition of property colitis.
10. the preparation method of the pharmaceutical composition for the treatment of ulcerative colitis according to claim 9, which is characterized in that
The method that the mixing uses ultrasonic vibration.
11. it is according to claim 1-8 treatment ulcerative colitis pharmaceutical composition preparation treatment people or
Application in the drug of person's animal ulcerative colitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611055105.2A CN106389451B (en) | 2016-11-25 | 2016-11-25 | A kind of pharmaceutical composition and its preparation method and application for treating inflammatory bowel disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611055105.2A CN106389451B (en) | 2016-11-25 | 2016-11-25 | A kind of pharmaceutical composition and its preparation method and application for treating inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106389451A CN106389451A (en) | 2017-02-15 |
| CN106389451B true CN106389451B (en) | 2019-06-07 |
Family
ID=58081673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611055105.2A Active CN106389451B (en) | 2016-11-25 | 2016-11-25 | A kind of pharmaceutical composition and its preparation method and application for treating inflammatory bowel disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106389451B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331023A (en) * | 2018-11-12 | 2019-02-15 | 沈阳药科大学 | The medical usage of enoxolone |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846705A (en) * | 2006-02-17 | 2006-10-18 | 武汉大学 | Application of glycyrrhizic acid and glycyrrhetic acid in preparing medicine for inflammatory enteropathy |
-
2016
- 2016-11-25 CN CN201611055105.2A patent/CN106389451B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846705A (en) * | 2006-02-17 | 2006-10-18 | 武汉大学 | Application of glycyrrhizic acid and glycyrrhetic acid in preparing medicine for inflammatory enteropathy |
Non-Patent Citations (4)
| Title |
|---|
| 人参皂苷Rg1对DSS诱导溃疡性结肠炎小鼠凝血功能的调节作用;郝微微等;《中国中西医结合消化杂志》;20130531;第21卷(第5期);第238-242页 |
| 半夏泻心汤对自身免疫性结肠炎模型大鼠的作用及其有效成分;野村麻乃, 贺玉琢译;《国外医学中医中药分册》;20051231;第27卷(第3期);第186页 |
| 吃好葱姜蒜 病痛少一半;骆景明;《家庭医学》;20031231;第12卷;第34页 |
| 小檗碱的研究进展;李芸兰等;《现代生物医学进展》;20120731;第12卷(第21期);第4173-4175页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106389451A (en) | 2017-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bartram | Bartram's encyclopedia of herbal medicine | |
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| US6063383A (en) | Pharmaceutical suppository composites for fever and influenza and method of producing the composites | |
| Rahim et al. | Anti-allergic rhinitis effects of medicinal plants and their bioactive metabolites via suppression of the immune system: a mechanistic review | |
| WO2020057029A1 (en) | Compatible composition of masticinic acid and myrrh terpene, preparation method therefor, and use thereof | |
| US20180369308A1 (en) | Chinese herbal medicine composition having a function of relieving hypothyroidism, preparation method and use thereof | |
| JP2020518596A (en) | Chinese herbal medicine extract effective for depression, its preparation method and use | |
| CN106389451B (en) | A kind of pharmaceutical composition and its preparation method and application for treating inflammatory bowel disease | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| WO2004028549A1 (en) | A coixenolide capsules for treating prostate disease | |
| KR20150078613A (en) | Anti-allergy composition comprising the extracts of aloeswood and concentratedunderground water as an active ingredient | |
| US11484562B2 (en) | Composition for preventing or treating obesity comprising natural mixture extracts | |
| CN102631397A (en) | Traditional Chinese medicine composition for improving cerebral blood circulation and preparation method thereof | |
| RU2546522C2 (en) | Pharmaceutical composition for treating drug dependence | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| Hartwich | The importance of immunological studies on Rhodiola rosea in the new effective and safe herbal drug discovery | |
| EP2402021A1 (en) | Pharmaceutical composition for treating or releiving inflammatory bowel disease | |
| JPH0733676A (en) | Composition for lowering blood suger value | |
| CN107648482A (en) | A kind of Chinese medicine composition for being used to treat nerve degenerative diseases | |
| Kumar et al. | Severity, types, factors affecting and strategy to overcome obesity | |
| CN101683427B (en) | Traditional Chinese medicine composition and preparation method thereof | |
| JPH06107553A (en) | Composition having analgesic function | |
| TWI262793B (en) | Composition for the treatment of systemic lupus erythematosus | |
| CN1279929C (en) | Chinese medicine for treating facial paralysis, preparing method and use | |
| RU2718050C2 (en) | Medicinal collection with tonic and adaptogenic action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230519 Address after: Building 7, West Jinmaoyuan Logistics Park, Houcang Village, Huanghe Ya Town, Decheng District, Dezhou City, Shandong Province, 253080 (Workshop 10, West Xinhua Industrial Park, Tanjiapu Village, Xinhua Street Office, Decheng District, Dezhou City, Shandong Province) Patentee after: Shandong Bintai Medical Technology Co.,Ltd. Address before: 250014, No. ten, No. 53, Lixia District, Ji'nan City, Shandong Province Patentee before: SHANDONG University OF TRADITIONAL CHINESE MEDICINE |